WEGOVY® is a once-weekly injectable medication used for chronic weight management. It contains semaglutide, a GLP-1 receptor agonist, and is designed to help reduce hunger and increase satiety.
- Active ingredient: Semaglutide
- Strength: 0.25 mg per dose in 0.5 mL solution
- Form: Single-use or multi-use pre-filled FlexTouch® pens
- Indicated for: Obese (BMI ≥30) or overweight (BMI ≥27) adults with weight-related conditions
- Dosing: Starts at 0.25 mg/week and increases gradually to 2.4 mg/week
- Device features: Hidden needle, automatic dosing, audible clicks
- Storage: Refrigerated (2–8°C) or ≤30°C for 28 days (single-use) / 8 weeks (multi-use)
WEGOVY® FLEXTOUCH® 0.25mg (Italian) Unique Technology
WEGOVY® uses the FlexTouch® injection system, designed for safe, precise, and user-friendly administration. It features automatic needle deployment and dose-locking mechanisms to minimize user error.
- FlexTouch® pen allows preset dosing with no manual adjustments
- Multi-use pens provide 4 doses per pen
- Needle remains hidden before and after use for improved patient comfort
- Visual cues (yellow bar in window) confirm full dose delivery
- Compatible with NovoFine® Plus needles
- Safety features include needle lock and one-way use
WEGOVY® FLEXTOUCH® 0.25mg (Italian) Indications
Wegovy® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with obesity or overweight with comorbidities.
- Adults with BMI ≥30 kg/m² (obese)
- Adults with BMI ≥27 and <30 kg/m² (overweight) with weight-related health issues
- Not approved for children and adolescents under 18 years old
- Not to be used during pregnancy or breastfeeding
- Not a substitute for insulin therapy in diabetes
WEGOVY® FLEXTOUCH® 0.25mg (Italian) Dosage and Administration
The starting dose is 0.25 mg once weekly for the first four weeks. The dose is gradually increased to reach a maintenance dose of 2.4 mg.
- Week 1–4: 0.25 mg once weekly
- Week 5–8: 0.5 mg
- Week 9–12: 1.0 mg
- Week 13–16: 1.7 mg
- Week 17+: 2.4 mg (maintenance dose)
- Injection sites: Upper arm, thigh, or abdomen
- Administer once weekly, on the same day each week, with or without food
- If a dose is missed and it’s within 5 days, take it; otherwise, skip the missed dose
WEGOVY® FLEXTOUCH® 0.25mg (Italian) Side Effects and Precautions
Wegovy® is associated with a range of side effects, most commonly gastrointestinal symptoms. There are serious warnings related to thyroid tumors, pancreatitis, and hypoglycemia (especially in patients on insulin or sulfonylureas).
- Very common (≥1 in 10): Nausea, vomiting, diarrhea, constipation, abdominal pain, fatigue, headache
- Common (≤1 in 10): Dizziness, dyspepsia, burping, flatulence, gastritis, reflux, hair loss, injection site reactions
- Uncommon (≤1 in 100): Pancreatitis, gallbladder disease, low blood sugar (without diabetes), fainting
- Rare: Severe allergic reactions (anaphylaxis), thyroid cancer
- Contraindicated in: MTC history, MEN 2 syndrome, pregnancy, breastfeeding
- Caution in: Diabetic eye disease, kidney or liver disease, heart failure, past depression or suicidal thoughts
WEGOVY® FLEXTOUCH® 0.25mg (Italian) Clinical Studies and Real-World Outcomes
Preclinical trials in rodents showed thyroid C-cell tumors. In humans, Wegovy™ demonstrated significant weight loss efficacy when used with lifestyle changes.
- Animal studies showed medullary thyroid carcinoma in rats and mice
- Human trials showed substantial weight loss, especially in patients adhering to diet and exercise
- Weekly semaglutide helped reduce body weight by up to 15% over time in clinical settings
- Further benefits include improvements in cardiometabolic risk factors
WEGOVY® FLEXTOUCH® 0.25mg (Italian) Drug Interactions
Wegovy® may interact with various drugs, particularly those that also affect heart rate or blood sugar levels. Caution is advised when used with other medications.
- Sulfonylureas or insulin: Risk of hypoglycemia increases
- May interact with:
- Antihypertensives
- Heart failure medications
- HIV drugs
- ADHD medications
- Appetite suppressants
- Decongestants
- Asthma medications
- Inform your doctor of all supplements and drugs you are using
WEGOVY® FLEXTOUCH® 0.25mg (Italian) Post-Treatment Care
Proper post-treatment care ensures continued safety and effectiveness. Patients should monitor for signs of dehydration, hypoglycemia, and mood changes.
- Hydration is important due to risk of vomiting/diarrhea
- Continue reduced-calorie diet and physical activity during and after treatment
- Monitor for thyroid symptoms (e.g., neck swelling, hoarseness)
- Check blood glucose levels if also on diabetes meds
- Safely dispose of used pens in sharps container
- Do not reuse pens or needles
- Inform healthcare provider if stopping treatment or becoming pregnant